Xeltis touts preclinical bioresorbable heart valve data

Xeltis today released early data on its bioresorbable heart valves built on endogenous tissue restoration technology, touting potential benefits of the regenerative approach to heart valve replacement. The Swiss medical device company’s technology is designed to promote endogenous tissue restoration using polymers structured as a resorbable “porous matrix.” The aim is to gradually replace the polymer structure with naturally regrown tissue, and the company is currently testing the system in pulmonary and aortic valves. “Our objective is to change the paradigm for heart valve treatment. If you think about it, today, what we do is kind of plumbing – we replace a faulty valve with another synthetic valve, made of animal tissue. Our objective is to allow the natural restoration of heart valves, letting the body heal itself, in a way. I think this is very exciting, and we’re going to see more and more data that supports the technology,” CEO Laurent Grandidier told MassDevice.com in an interview. Early preclinical data on the company’s aortic valve was presented today at the EuroPCR 2017 conference in Paris, and showed good hemodynamic performance fully functional valves in vivo at 6-months post implantation, according to a company press release. “The next big milestone will be when we start implanting aortic valves in patients in a clinical trial. That will take a bit of time, most likely a year and a half, maybe 2 years, but that’...
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Replacement Heart Valves Research & Development Xeltis Source Type: news